Abbott Laboratories Third Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Abbott Laboratories (NYSE:ABT) will unveil its latest earnings on Wednesday, October 19, 2011. Abbott Laboratories is a pharmaceuticals health care company, whose main line of business is in the discovery, development, manufacture, and sale of a broad range of health care products. Its customers include wholesalers, hospitals and commercial laboratories.

Abbott Laboratories Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of $1.17 per share, a rise of 11.4% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from $1.16. Between one and three months ago, the average estimate moved up. It has been unchanged at $1.17 during the last month. Analysts are projecting profit to rise by 11.3% versus last year to $4.64.

Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by one cent, reporting net income of $1.12 per share against a mean estimate of profit of $1.11 per share.

Investing Insights: has a Stock Chart Technical Analysts Dream About.

Wall St. Revenue Expectations: Analysts are projecting a rise of 11.2% in revenue from the year-earlier quarter to $9.65 billion.

Analyst Ratings: Analysts are bullish on this stock with 11 analysts rating it as a buy, none rating it as a sell and eight rating it as a hold.

A Look Back: In the second quarter, profit rose 50.4% to $1.94 billion ($1.23 a share) from $1.29 billion (83 cents a share) the year earlier, exceeding analyst expectations. Revenue rose 9% to $9.62 billion from $8.83 billion.

Key Stats:

The increase in profit in the second quarter broke a streak of three consecutive quarters of year-over-year profit decreases. Net income dropped 13.9% in the first quarter, 6.4% in the fourth quarter of the last fiscal year and 39.8% in the third quarter of the last fiscal year.

Revenue has risen the past four quarters. Revenue rose 17.4% in the first quarter from the year earlier, climbed 13.4% in the fourth quarter of the last fiscal year from the year-ago quarter and 11.8% in the third quarter of the last fiscal year.

Competitors to Watch: Pfizer Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), Novartis AG (NYSE:NVS), Roche Holding Ltd. (RHHBY), GlaxoSmithKline plc (NYSE:GSK), Bristol Myers Squibb Co. (NYSE:BMY), Merck & Co., Inc. (NYSE:MRK), Medtronic, Inc. (NYSE:MDT), Boston Scientific Corp. (NYSE:BSX), and Sanofi-Aventis SA (NYSE:SNY).

Stock Price Performance: During August 17, 2011 to October 13, 2011, the stock price had risen $2.46 (5%) from $49.69 to $52.15. The stock price saw one of its best stretches over the last year between October 3, 2011 and October 12, 2011 when shares rose for eight-straight days, rising 5.3% (+$2.64) over that span. It saw one of its worst periods between July 22, 2011 and August 2, 2011 when shares fell for eight-straight days, falling 5.2% (-$2.73) over that span. Shares are up $5.98 (+13%) year to date.

(Source: Xignite Financials)

Investing Insights: has a Stock Chart Technical Analysts Dream About.